Gynecologic Oncology Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Gynecologic Oncology Group sits in the top decile of US sponsors by registered trial count (#189 of 15,742 sponsors by registered trial count).
Gynecologic Oncology Group: 154 sponsored US clinical trials, 1 recruiting.
Gynecologic Oncology Group sponsors 154 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 115 completed. 27 of these trials are in Phase 3-4 (later-stage) and 107 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cervical Cancer, with 6 trials.
Top-decile sponsor footprint
Gynecologic Oncology Group ranks in the top decile of sponsors by registered trial count (#189 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
115 of 151 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
154 total, page 1 of 4
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
NCT01000259
Abemaciclib and Letrozole to Treat Endometrial Cancer
NCT04393285
Ribociclib and Letrozole Treatment in Ovarian Cancer
NCT03673124
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT01720173
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01642082
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
NCT01406769
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01489371
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
NCT01533207
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01225887
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT01210222
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
NCT01275664
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01266460
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01267253
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT01295489
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01294293
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01118052
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01039207
Prognostic Biomarkers in Patients With Endometrial Cancer
NCT01208467
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
NCT00857545
Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
NCT01098630
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
NCT01139957
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01080521
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer
NCT01198171
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT01164735
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
NCT01344837
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00888173
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00939809
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
NCT00814086
Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00820898
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
NCT00691301
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT00671788
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
NCT00445887
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
NCT00569673
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
NCT00575952
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00574951
Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer
NCT00577317
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
NCT00521118
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
NCT00054444
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
NCT00899093
Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia
NCT00503581
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00499252
Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00499031
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
NCT00379145
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00459290
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes
NCT00460356
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00309959
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00407758
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
NCT00352300
Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT00087100
Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer
NCT00217633
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 86 |
| Phase 3 | 27 |
Therapeutic Areas
What is open in the Gynecologic Oncology Group pipeline
1 recruiting of 154 indexed (1% open); 115 completed (75%).
Phase mix: 27 late (III/IV) vs 107 early (I/II) (early-phase heavy).
Top condition: Cervical Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Gynecologic Oncology Group: open-pipeline peers nationwide
Peers matched on 154 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Gynecologic Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 154 trials (± recruiting share)
- Sanofi Pasteur, a Sanofi Company · 153 trials · 2% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Galderma R&D · 158 trials · 4% recruiting
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
Sponsors near 1% open enrollment (± trial volume)
- Mylan Pharmaceuticals · 1% recruiting · 146 trials
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- Shire · 0% recruiting · 245 trials
- Abbott Nutrition · 1% recruiting · 89 trials
Related
What to do with this Gynecologic Oncology Group page
154 registered trials is a research-attention snapshot, not an endorsement of Gynecologic Oncology Group or any single study.
- 1 of Gynecologic Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cervical Cancer is the condition Gynecologic Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cervical Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Gynecologic Oncology Group pipeline card: 154 registered trials from official public datasets.Report a data error.